Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Shots:
- The P-III NALA trial involves assessing of neratinib + capecitabine vs Tykerb (lapatinib) + capecitabine in 621 patients in ratio (1:1) with 3L HER2-positive metastatic breast cancer
- P-III NALA Trial results: mPFS (8.8 mos. vs 6.6 mos.); mOS (21.0 mos. vs 18.7 mos.); mean OS @48 mos. (24.0 mos. vs 22.2 mos.); overall cumulative incidence of CNS metastases (22.8% vs 29.2%); DOR (8.54 mos. vs 5.55 mos.); TEAEs (10.9% vs 14.5%)
- PB272 is a tyrosine kinase inhibitor and its oral formulation has received the US FDA’s approval for the extended adjuvant treatment in adults with early stage HER2-overexpressed/amplified breast cancer in Jul’17- marketed as Nerlynx (neratinib) tablets in the US
Click here to read full press release/ article | Ref: Puma Biotechnology | Image: ID Works Global
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
